SGMO
Sangamo Therapeutics·NASDAQ
--
--(--)
--
--(--)
SGMO fundamentals
Sangamo Therapeutics (SGMO) expects to report earnings on Mar 30, 2026, with estimated revenue of 40.23M (YoY +432.71%), and EPS at 0.009 (YoY +108.18%).
Revenue estimate / YoY
40.23M
+432.71%
EPS estimate / YoY
0.009
+108.18%
Report date
Mar 30, 2026
SGMO Earnings Call Summary for Q4,2025
- Fabry BLA Progress: Rolling submission underway; clinical and preclinical modules submitted. CMC completion expected by summer 2026, contingent on funding. ST-920 data show stabilized kidney and cardiac function in patients.
- Neurology Expansion: ST-503 Phase I/II study active at 6 sites; received FDA Fast Track for SFN. ST-506 advancing with toxicology study complete.
- Partnership Focus: Prioritizing Fabry commercialization partner; discussions with multiple new partners despite regulatory delays. $130M+ raised since 2025 through licensing and equity.
- Capsid Innovation: Third STAC-BBB capsid agreement with Eli Lilly for CNS targets. AAV9 used for ST-503 due to historical intrathecal efficacy.
EPS
Actual | -0.37 | -0.26 | -0.01 | -0.29 | -0.32 | -0.33 | -0.33 | -0.26 | -0.3 | -0.29 | -0.34 | -0.32 | 0.125 | -0.66 | -0.59 | -0.34 | -0.27 | -0.18 | 0.04 | -0.11 | -0.14 | -0.08 | -0.11 | |||||||||||
Forecast | -0.2771 | 0.1088 | -0.242 | -0.2127 | -0.2936 | -0.3131 | -0.3369 | -0.3455 | -0.3111 | -0.3527 | -0.3555 | -0.36 | -0.3282 | -0.3364 | -0.3189 | -0.2563 | -0.2138 | -0.1467 | -0.0153 | -0.0913 | -0.1173 | -0.0101 | -0.0005 | 0.009 | ||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -33.53% | -338.97% | +95.87% | -36.34% | -8.99% | -5.40% | +2.05% | +24.75% | +3.57% | +17.78% | +4.36% | +11.11% | +138.09% | -96.20% | -85.01% | -32.66% | -26.29% | -22.70% | +361.44% | -20.48% | -19.35% | -692.08% | -21900.00% | 0.00% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 13.08M | 21.55M | 57.76M | 25.80M | 26.28M | 27.87M | 28.56M | 28.00M | 28.23M | 29.38M | 26.46M | 27.23M | 158.00M | 6.83M | 9.40M | 2.04M | 481.00K | 356.00K | 49.40M | 7.55M | 6.44M | 18.31M | 581.00K | -- |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.74M | 102.71M | 26.55M | 31.42M | 28.49M | 26.53M | 25.96M | 26.82M | 27.29M | 24.63M | 26.59M | 26.86M | 24.07M | 16.75M | 9.36M | 8.11M | 6.36M | 6.88M | 20.92M | 11.70M | 8.90M | 31.68M | 34.40M | 40.23M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -42.49% | -79.02% | +117.55% | -17.89% | -7.74% | +5.04% | +10.03% | +4.39% | +3.46% | +19.28% | -0.48% | +1.39% | +556.56% | -59.19% | +0.41% | -74.81% | -92.43% | -94.83% | +136.18% | -35.46% | -27.67% | -42.22% | -98.31% | 0.00% |
Earnings Call
You can ask Aime
What were the key takeaways from Sangamo Therapeutics’s earnings call?What does Sangamo Therapeutics do and what are its main business segments?What guidance did Sangamo Therapeutics's management provide for the next earnings period?What is the revenue and EPS growth rate for Sangamo Therapeutics year over year?What is Sangamo Therapeutics's latest dividend and current dividend yield?Did Sangamo Therapeutics beat or miss consensus estimates last quarter?What factors drove the changes in Sangamo Therapeutics's revenue and profit?What were the key takeaways from Sangamo Therapeutics's earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
